|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
On World Sight Day, Merck & Co., Inc. (MRK) and Partners Mark 25 Years of Successful Collaboration to Help Eliminate River Blindness
10/11/2012 9:58:44 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Today on World Sight Day, 25 years after Merck (known as MSD outside the United States and Canada) started the MECTIZAN® Donation Program (MDP), the company celebrates with partners important progress in the elimination of river blindness, one of the leading causes of preventable blindness worldwide. In October 1987, Merck made the decision to donate the medication MECTIZAN (ivermectin) for the treatment of river blindness (onchocerciasis) – as much as needed, for as long as needed – to eliminate the disease as a public health problem. MDP efforts are focused in Africa, Latin America and Yemen, where river blindness is endemic. In 1998, Merck expanded the MDP to include the elimination of lymphatic filariasis (LF), in African countries and Yemen where it co-exists with river blindness. World leaders come together to discuss the role of MDP in establishing a platform for disease control in a landmark event titled: 'Disease Elimination in the 21st Century.'
|
|
|
|
|
|
|
|
|
|
|